Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2008 3
2009 3
2010 2
2012 5
2013 4
2014 1
2015 8
2016 6
2017 4
2018 5
2019 6
2020 5
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

51 results
Results by year
Filters applied: . Clear all
Page 1
Molecular Breast Imaging in Clinical Practice.
Dibble EH, Hunt KN, Ehman EC, O'Connor MK. Dibble EH, et al. AJR Am J Roentgenol. 2020 Aug;215(2):277-284. doi: 10.2214/AJR.19.22622. Epub 2020 Jun 17. AJR Am J Roentgenol. 2020. PMID: 32551908 Review.
The purpose of this article is to review clinical uses and image interpretation of molecular breast imaging (MBI) and clarify radiation risks. CONCLUSION. MBI detects additional cancers compared with conventional imaging in women with dense breasts and …
The purpose of this article is to review clinical uses and image interpretation of molecular breast imaging (MBI) and c …
Molecular breast imaging.
O'Connor M, Rhodes D, Hruska C. O'Connor M, et al. Expert Rev Anticancer Ther. 2009 Aug;9(8):1073-80. doi: 10.1586/era.09.75. Expert Rev Anticancer Ther. 2009. PMID: 19671027 Free PMC article. Review.
Molecular breast imaging (MBI) is a new nuclear medicine technique that utilizes small semiconductor-based gamma-cameras in a mammographic configuration to provide high-resolution functional images of the breast. Current studies with MBI have used Tc-9
Molecular breast imaging (MBI) is a new nuclear medicine technique that utilizes small semiconductor-based gamma-camera
Dose Reduction in Molecular Breast Imaging With a New Image-Processing Algorithm.
Tao AT, Hruska CB, Conners AL, Hunt KN, Swanson TN, Tran TD, Manduca A, Borges L, Maidment ADA, Lake D, Johnson MP, Carter RE, Rhodes DJ, O'Connor MK. Tao AT, et al. AJR Am J Roentgenol. 2020 Jan;214(1):185-193. doi: 10.2214/AJR.19.21582. Epub 2019 Oct 8. AJR Am J Roentgenol. 2020. PMID: 31593516
The purpose of this study was to determine whether application of a proprietary image-processing algorithm would allow a reduction in the necessary administered activity for molecular breast imaging (MBI) examinations. MATERIALS AND METHODS. ...Two breast
The purpose of this study was to determine whether application of a proprietary image-processing algorithm would allow a reduction in the ne …
Screening Algorithms in Dense Breasts: AJR Expert Panel Narrative Review.
Berg WA, Rafferty EA, Friedewald SM, Hruska CB, Rahbar H. Berg WA, et al. AJR Am J Roentgenol. 2021 Feb;216(2):275-294. doi: 10.2214/AJR.20.24436. Epub 2020 Dec 23. AJR Am J Roentgenol. 2021. PMID: 32903054 Review.
Screening mammography reduces breast cancer mortality; however, when used to examine women with dense breasts, its performance and resulting benefits are reduced. Increased breast density is an independent risk factor for breast cancer. Digital breast
Screening mammography reduces breast cancer mortality; however, when used to examine women with dense breasts, its performance and re …
Idiopathic granulomatous mastitis: imaging update and review.
Fazzio RT, Shah SS, Sandhu NP, Glazebrook KN. Fazzio RT, et al. Insights Imaging. 2016 Aug;7(4):531-9. doi: 10.1007/s13244-016-0499-0. Epub 2016 May 24. Insights Imaging. 2016. PMID: 27221974 Free PMC article. Review.
Axillary lymph nodes were reactive in appearance at ultrasound. Molecular breast imaging performed in one case showed mild focal asymmetric radiotracer uptake. CONCLUSION: IGM is a rapidly progressive rare inflammatory condition of the breast resulting …
Axillary lymph nodes were reactive in appearance at ultrasound. Molecular breast imaging performed in one case showed m …
Supplemental screening in the dense breast: does molecular breast imaging have a role?
Rhodes DJ. Rhodes DJ. Menopause. 2020 Jan;27(1):110-112. doi: 10.1097/GME.0000000000001471. Menopause. 2020. PMID: 31880677
With the passage of a 2019 US federal law directing FDA to ensure that mammography facilities provide a summary to patients categorizing their breast density and explaining how it can influence mammography accuracy, providers will increasingly be called on to discuss the o …
With the passage of a 2019 US federal law directing FDA to ensure that mammography facilities provide a summary to patients categorizing the …
Background Parenchymal Uptake on Molecular Breast Imaging and Breast Cancer Risk: A Cohort Study.
Hruska CB, Geske JR, Conners AL, Whaley DH, Rhodes DJ, O'Connor MK, Carter RE, Scott CG, Vachon CM. Hruska CB, et al. AJR Am J Roentgenol. 2021 May;216(5):1193-1204. doi: 10.2214/AJR.20.23854. Epub 2021 Mar 3. AJR Am J Roentgenol. 2021. PMID: 32755210
BACKGROUND. Background parenchymal uptake (BPU) on molecular breast imaging (MBI) was identified in a case-control study as a breast cancer risk factor beyond mammographic density. ...In postmenopausal women, BPU provides incremental discrimination in …
BACKGROUND. Background parenchymal uptake (BPU) on molecular breast imaging (MBI) was identified in a case-control stud …
Background parenchymal uptake during molecular breast imaging and associated clinical factors.
Hruska CB, Rhodes DJ, Conners AL, Jones KN, Carter RE, Lingineni RK, Vachon CM. Hruska CB, et al. AJR Am J Roentgenol. 2015 Mar;204(3):W363-70. doi: 10.2214/AJR.14.12979. AJR Am J Roentgenol. 2015. PMID: 25714323 Free PMC article.
The purposes of this study were to describe the prevalence of background parenchymal uptake categories observed at screening molecular breast imaging (MBI) and to examine the association of background parenchymal uptake with mammographic density and other cli …
The purposes of this study were to describe the prevalence of background parenchymal uptake categories observed at screening molecular
Molecular Breast Imaging: Administered Activity Does Not Require Adjustment Based on Patient Size.
Tran TD, Ellingson LR, Swanson TN, Solberg CM, O'Connor MK, Hruska CB. Tran TD, et al. J Nucl Med Technol. 2018 Sep;46(3):265-267. doi: 10.2967/jnmt.117.203869. Epub 2018 Mar 29. J Nucl Med Technol. 2018. PMID: 29599399 Free article.
At our institution, molecular breast imaging (MBI) is performed with 300 MBq of (99m)Tc-sestamibi for all patients. ...Breast thickness was measured as the distance between the 2 detectors. ...
At our institution, molecular breast imaging (MBI) is performed with 300 MBq of (99m)Tc-sestamibi for all patients. ... …
Quantitative background parenchymal uptake on molecular breast imaging and breast cancer risk: a case-control study.
Hruska CB, Geske JR, Swanson TN, Mammel AN, Lake DS, Manduca A, Conners AL, Whaley DH, Scott CG, Carter RE, Rhodes DJ, O'Connor MK, Vachon CM. Hruska CB, et al. Breast Cancer Res. 2018 Jun 5;20(1):46. doi: 10.1186/s13058-018-0973-3. Breast Cancer Res. 2018. PMID: 29871661 Free PMC article.
BACKGROUND: Background parenchymal uptake (BPU), which refers to the level of Tc-99m sestamibi uptake within normal fibroglandular tissue on molecular breast imaging (MBI), has been identified as a breast cancer risk factor, independent of mammographic …
BACKGROUND: Background parenchymal uptake (BPU), which refers to the level of Tc-99m sestamibi uptake within normal fibroglandular tissue on …
51 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page